Hayato Tada

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Journal: Journal of atherosclerosis and thrombosis

Published: July 01, 2026

Distribution of Lipoprotein(a) Levels Among Children with Elevated Low-Density Lipoprotein Cholesterol Identified Through Universal Pediatric Lipid Screening.

Journal: Journal of atherosclerosis and thrombosis

Published: June 10, 2026

Current and Future Perspectives of LDL-C Lowering Therapies 2026.

Journal: Journal of atherosclerosis and thrombosis

Published: May 27, 2026

Severe HDL-C Deficiency Caused by Acquired LCAT Deficiency: A Case Report with Lipidomic Profiling and Anti-LCAT Autoantibody Detection.

Journal: Internal medicine (Tokyo, Japan)

Published: May 24, 2026

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia.

Journal: Atherosclerosis plus

Published: May 22, 2026

It's Time to Measure Lp(a): Recognizing a Neglected Cardiovascular Risk.

Journal: Journal of atherosclerosis and thrombosis

Published: May 10, 2026

Lipoprotein(a) Distribution and Cardiovascular Risk in Japan: Insights from a Multi-center LEAP Study.

Journal: Journal of atherosclerosis and thrombosis

Published: May 06, 2026

An Improved Prognosis in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in LDL-Lowering Therapy.

Journal: Journal of atherosclerosis and thrombosis

Published: March 29, 2026

Impact of Genetic Testing Among Patients With Familial Hypercholesterolemia on Adverse Cardiovascular Events　- The Hokuriku-Plus Familial Hypercholesterolemia Registry Study.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 22, 2026

Beyond Familial Hypercholesterolemia: Your Feet can Help Predict Your Coronary Atherosclerosis.

Journal: Journal of atherosclerosis and thrombosis

Published: March 08, 2026

Unanswered Questions About the Relationship Between Lipoprotein(a) and Atherosclerotic Cardiovascular Disease.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 01, 2026

Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data.

Journal: Internal medicine (Tokyo, Japan)

Published: February 23, 2026

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Distribution of Lipoprotein(a) Levels Among Children with Elevated Low-Density Lipoprotein Cholesterol Identified Through Universal Pediatric Lipid Screening.

Distribution of Lipoprotein(a) Levels Among Children with Elevated Low-Density Lipoprotein Cholesterol Identified Through Universal Pediatric Lipid Screening.

Current and Future Perspectives of LDL-C Lowering Therapies 2026.

Current and Future Perspectives of LDL-C Lowering Therapies 2026.

Severe HDL-C Deficiency Caused by Acquired LCAT Deficiency: A Case Report with Lipidomic Profiling and Anti-LCAT Autoantibody Detection.

Severe HDL-C Deficiency Caused by Acquired LCAT Deficiency: A Case Report with Lipidomic Profiling and Anti-LCAT Autoantibody Detection.

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia.

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia.

It's Time to Measure Lp(a): Recognizing a Neglected Cardiovascular Risk.

It's Time to Measure Lp(a): Recognizing a Neglected Cardiovascular Risk.

Lipoprotein(a) Distribution and Cardiovascular Risk in Japan: Insights from a Multi-center LEAP Study.

Lipoprotein(a) Distribution and Cardiovascular Risk in Japan: Insights from a Multi-center LEAP Study.

An Improved Prognosis in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in LDL-Lowering Therapy.

An Improved Prognosis in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in LDL-Lowering Therapy.

Impact of Genetic Testing Among Patients With Familial Hypercholesterolemia on Adverse Cardiovascular Events - The Hokuriku-Plus Familial Hypercholesterolemia Registry Study.

Impact of Genetic Testing Among Patients With Familial Hypercholesterolemia on Adverse Cardiovascular Events - The Hokuriku-Plus Familial Hypercholesterolemia Registry Study.

Beyond Familial Hypercholesterolemia: Your Feet can Help Predict Your Coronary Atherosclerosis.

Beyond Familial Hypercholesterolemia: Your Feet can Help Predict Your Coronary Atherosclerosis.

Unanswered Questions About the Relationship Between Lipoprotein(a) and Atherosclerotic Cardiovascular Disease.

Unanswered Questions About the Relationship Between Lipoprotein(a) and Atherosclerotic Cardiovascular Disease.

Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data.

Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data.

Impact of Genetic Testing Among Patients With Familial Hypercholesterolemia on Adverse Cardiovascular Events　- The Hokuriku-Plus Familial Hypercholesterolemia Registry Study.

Impact of Genetic Testing Among Patients With Familial Hypercholesterolemia on Adverse Cardiovascular Events　- The Hokuriku-Plus Familial Hypercholesterolemia Registry Study.